NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT03905967,TACE With Lenvatinib Versus Lenvatinib Alone in in First-line Treatment of Advanced HCC,https://clinicaltrials.gov/study/NCT03905967,TACE,UNKNOWN,"This trial is is an open label, multicenter, randomized controlled phase 3 clinical trial. The purpose is to compare the efficacy and safety of lenvatinib plus TACE with lenvatinib alone for advanced HCC patients.",NO,Advanced Hepatocellular Carcinoma,PROCEDURE: TACE|DRUG: Lenvatinib,"Overall survival, Defined as the time from randomization to death for any cause., two years","Time to progression, Defined as the time from randomization to disease progression., two years",,Sun Yat-sen University,,ALL,"ADULT, OLDER_ADULT",PHASE3,336,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,20190031,2019-06-16,2023-04-15,2023-06-15,2019-04-08,,2019-08-20,"The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, 510080, China",
